TEL AVIV, Israel, May 15, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced its financial results for the first quarter ended March 31, 2014. - See more at: http://www.globenewswire.com/news-release/2014/05/15/636744/10081854/en/Alcobra-Announces-First-Quarter-Financial-Results-and-Corporate-Update.html#sthash.ZqVmxAH7.dpuf
Help employers find you! Check out all the jobs and post your resume.
